Market Overview

Oppenheimer Reiterates Outperform, Raises PT to $33 on ViroPharma


Oppenheimer maintains its Outperform rating on ViroPharma (NASDAQ: VPHM) as new Vancocin label provides three years of exclusivity.

Oppenheimer says, “Modernization of Vancocin Label Likely to Provide Three-Year Exclusivity. Vancocin's modernized label includes updated safety/efficacy data related to treating C. difficile. As such, we believe Vancocin meets requirements for exclusivity beginning today (anticipate FDA confirmation during 1Q12) through YE2014, quelling concerns of a generic Vancocin entrant which was largely expected to occur during 2012.”

VPHM closed at $27.80 per share on Wednesday.

Posted-In: OppenheimerAnalyst Color Price Target Pre-Market Outlook Analyst Ratings


Related Articles (VPHM)

View Comments and Join the Discussion!

Partner Center